← Back to Search

Vitamin D Analog

Chemotherapy + Paricalcitol for Pancreatic Cancer (NABPLAGEMD Trial)

Phase 2
Waitlist Available
Led By Erkut Borazanci, MD
Research Sponsored by HonorHealth Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the end of 3 cycles (each cycle is 21 days)
Awards & highlights

NABPLAGEMD Trial Summary

This trial is testing a new combination of drugs to see if it's effective in treating pancreatic cancer that has spread.

Who is the study for?
This trial is for adults with untreated metastatic pancreatic ductal adenocarcinoma. Participants must have a life expectancy of at least 12 weeks, measurable tumor lesions, and be able to consent to the study's procedures including biopsies. Women should not be pregnant or breastfeeding and both genders must practice birth control during the study.Check my eligibility
What is being tested?
The trial tests if combining paclitaxel protein bound (a chemotherapy drug), gemcitabine, cisplatin (another chemo drug), and paricalcitol can effectively treat individuals with metastatic pancreatic cancer who haven't had previous treatments for their advanced disease.See study design
What are the potential side effects?
Potential side effects may include nausea, fatigue, hair loss from chemotherapy drugs like paclitaxel protein bound and cisplatin; as well as possible kidney issues related to paricalcitol. Each patient's experience with side effects could vary.

NABPLAGEMD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the end of 3 cycles (each cycle is 21 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and at the end of 3 cycles (each cycle is 21 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pathologic Complete Response Rate
Secondary outcome measures
Carbohydrate Antigen 19-9 (CA19-9) value
Parathyroid Hormone (PTH)
Vitamin D 25-hydroxy (OH)
+3 more

NABPLAGEMD Trial Design

1Treatment groups
Experimental Treatment
Group I: Paricalcitol (Zemplar)Experimental Treatment1 Intervention
Participants will be treated with the regimen according to the study protocol. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization and undergo imaging to determine response, if any.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Paricalcitol (Zemplar)
2018
Completed Phase 2
~20

Find a Location

Who is running the clinical trial?

HonorHealth Research InstituteLead Sponsor
25 Previous Clinical Trials
895 Total Patients Enrolled
Abramson Cancer Center at Penn MedicineOTHER
383 Previous Clinical Trials
144,886 Total Patients Enrolled
Mayo ClinicOTHER
3,175 Previous Clinical Trials
3,758,150 Total Patients Enrolled

Media Library

Paricalcitol (Vitamin D Analog) Clinical Trial Eligibility Overview. Trial Name: NCT03415854 — Phase 2
Pancreatic Cancer Research Study Groups: Paricalcitol (Zemplar)
Pancreatic Cancer Clinical Trial 2023: Paricalcitol Highlights & Side Effects. Trial Name: NCT03415854 — Phase 2
Paricalcitol (Vitamin D Analog) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03415854 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Paricalcitol (Zemplar) received FDA sign-off?

"Paricalcitol (Zemplar) is currently being trialled in Phase 2, so there is some safety data supporting its use but efficacy has not yet been proven."

Answered by AI

What is the maximum participation for this clinical trial?

"Presently, this clinical trial is not searching for new patients. This specific study was posted on 1/31/2018 and last edited on 2/16/2022. However, there are 1175 other trials for adenocarcinoma and 1564 trials for Paricalcitol (Zemplar) that are still recruiting patients."

Answered by AI

Can people with the qualifying condition participate in this research?

"This particular clinical trial is not looking for new patients at the moment, however that could change in the future. The last update on this study was February 16th, 2022 and it was originally posted January 31st, 2018. There are 2,739 other trials that are currently open to new participants."

Answered by AI

What is the primary purpose of Paricalcitol (Zemplar)?

"Paricalcitol (Zemplar) is most often used as part of adjuvant therapy for patients that have already undergone treatment with anthracyclines. Additionally, this medication can be given to patients suffering from neoplasm metastasis, locally advanced non-small cell lung cancer, and metastatic bladder cancer."

Answered by AI
~2 spots leftby Mar 2025